Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quest Diagnostics Introduces bioMerieux THxID®-BRAF Test

Published: Wednesday, June 11, 2014
Last Updated: Wednesday, June 11, 2014
Bookmark and Share
A companion diagnostic to advance precision medicine for melanoma.

Quest Diagnostics has introduced a new cancer test service based on the FDA-approved THxID®-BRAF test from bioMerieux, a world leader in the field of in vitro diagnostics. The THxID®-BRAF test is a companion diagnostic for two treatments for melanoma.

The test is intended to be used as an aid in selecting patients with melanoma whose tumors carry the BRAF V600E mutation for treatment with dabrafenib [Tafinlar®] and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib [Mekinist™].

The U.S. Food and Drug Administration approved the two drugs and the gene test as a companion diagnostic in May 2013. The drugs, manufactured by GlaxoSmithKline, treat patients with advanced (metastatic) or unresectable (cannot be surgically removed) melanoma, the most dangerous type of skin cancer. bioMerieux manufactures the THxID-BRAF test kit.

Dermatologists, oncologists, hospital pathologists and other physicians may order the test through Quest Diagnostics, including its AmeriPath and Dermpath businesses, which specialize in anatomic and dermatologic pathology testing.

"Because of this relationship with Quest, many more doctors will have access to THxID®-BRAF test. This means that more patients with advance melanoma will benefit from the optimized treatment that results when the THxID®-BRAF test is used in designing their regimens," said Dr. Samuel Bozzette, Vice President, Medical Affairs - Americas, bioMerieux, Inc.

"The addition of the THxID-BRAF test to our menu reflects our commitment to offering the most advanced dermatopathology testing available and to the field of precision medicine, which aims to improve outcomes based on a holistic clinical understanding of the patient," said Frederic Waldman MD, PhD, medical director, cancer diagnostics, Quest Diagnostics. "The THxID-BRAF test further extends the services we provide for melanoma and other cancers across a continuum of care, giving physicians insights to help guide treatment decisions and empower better health."

"Because Quest reaches about half of the practicing physicians and hospitals in the United States, patients and providers will now have access to the THxID-BRAF test on a truly broad national scale," added Dr. Waldman.

In addition to the bioMerieux test, Quest offers the FDA-cleared cobas® 4800 BRAF V600 Mutation Test, which detects the BRAF V600E mutation in order to help physicians select patients for treatment with vemurafenib, an oral medicine designed to treat patients whose melanoma tumors harbor the mutation. Quest also offers a laboratory-developed test for assessing BRAF mutations in melanoma, thyroid, and colorectal cancers based on sanger sequencing.

BRAF is a gene implicated in several cancers, including melanoma. Approximately half of melanomas arising in the skin have a BRAF gene mutation.

Melanoma is the leading cause of death from skin disease. The National Cancer Institute estimates 76,100 Americans will be diagnosed with melanoma and 9,710 will die from the disease in 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Zika Test from Quest Diagnostics Authorized by the FDA
Company has announced that it has received a U.S. FDA emergency use authorization for the Zika Virus RT-PCR test.
Saturday, April 30, 2016
Quest Diagnostics Sponsors Women's Health Movement
Company offers 10,000 vouchers for free wellness screenings as national presenting sponsor.
Wednesday, May 02, 2012
Scientific News
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
UTSW Creates Nanoparticles That Target Lung Cancer Cells
Researchers at UTSW have developed a synthetic polymers that could deliver nucleic acid drugs while possessing enough structural diversity to discover cancer cell-specific nanoparticles.
Delivering Beneficial Bacteria
Method that transports microbes through the stomach to the intestine may benefit human health.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!